If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment CSU is a chronic skin disease with underlying type 2 inflammation that can cause debilitating hives and recurring itch in young children TARRYTOWN, N.Y. and PARIS, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency’s Committee for M ...

Million Concurrent Private Placement with NexGen Energy[All monetary amounts are expressed in Canadian Dollars, unless otherwise indicated. TORONTO, Jan. 27, 2026 /PRNewswire/ - IsoEnergy Ltd. (NYSE...]### IsoEnergy Completes C$57.5 Million Bought Deal Financing[All monetary amounts are expressed in Canadian Dollars, unless otherwise indicated. TORONTO, Jan. 27, 2026 /PRNewswire/ - IsoEnergy Ltd. (NYSE...][More Releases From This Source]## Explore[Oil & Energy][Utilities][Mining][Mining][News Releases in Si ...

Caris Life Sciences Inc. (NASDAQ:CAI) shares are up during Friday’s premarket session following better-than-expected fourth-quarter earnings and a significant interim readout from the company’s Achieve 1 study.Sales More Than DoubledCaris Life Sciences on Thursday reported fourth-quarter earnings of 28 cents compared to the consensus loss of 3 cents.Sales for the quarter jumped 125% year over year to $292.89 million, beating the consensus of $208.63 million.The increase was driven primarily by a 199% growth ...

of the Q3 2026 MD&A, the Fiscal 2025 MD&A, the Fiscal 2025 AIF and the Company's other publicly filed documents can be accessed under the Company's profile on SEDAR+ at [www.sedarplus.com].The Company cautions that the foregoing list of risk factors and uncertainties is not exhaustive and other factors could also adversely affect its results. We operate in a highly competitive and rapidly changing environment in which new risks often emerge. It is not possible for management to predict all risks, nor assess ...

Company Announcement - Brunswick Exploration Inc. has appointed Charles Kodors as Vice President – International Projects, recognizing his contributions to the company's international portfolio since its rebranding in 2020 [1][2] - Mr. Kodors has over 15 years of experience in the mining and exploration industry, previously serving as Exploration Manager for Osisko Metals and Senior Exploration Geologist for Kirkland Lake Gold [2] Stock Options and DSUs - The company granted 186,566 deferred share units (DSUs) to non-executive directors at a fair market value of $0.268 per DSU, which will vest one year from the grant date [3] - The Board of Directors approved the grant of incentive stock options to purchase up to 3,515,000 common shares at an exercise price of $0.235 per share, subject to a three-year vesting period and a five-year term [4] Company Overview - Brunswick Exploration is focused on grassroots exploration for lithium in Canada, Greenland, and Saudi Arabia, with a significant emphasis on the Mirage project, which has an Inferred Mineral Resource Estimate of 52.2 million tonnes grading 1.08% Li2O [5]

Core Viewpoint - Abaxx Technologies Inc. has launched trading for Enwex Netherlands, France, and Spain Onshore Wind futures, providing standardized tools to manage wind generation risk across major European renewable markets [1][2]. Group 1: Product Launch and Features - The newly introduced wind futures contracts are designed to hedge against the variability in electricity output caused by wind generation, which affects revenue and utilization for market participants [2]. - Each contract is euro-denominated, financially settled, and indexed to the respective Enwex Wind country index, which measures forecast wind conditions at 100 meters and expresses standardized generation utilization rates in €/MWh [3]. - Trading for these contracts is available from 1000 to 2400 SGT, Monday to Friday, excluding Singapore public holidays [4]. Group 2: Market Impact and Infrastructure - The introduction of wind futures across six major power markets establishes a consistent set of weather-indexed benchmarks, facilitating reference pricing for wind generation variability across different jurisdictions [4]. - Abaxx Exchange aims to support the transition to a low-carbon economy by providing market infrastructure that includes centrally-cleared, physically-deliverable futures contracts in various commodities [7]. Group 3: Company Overview - Abaxx Technologies focuses on creating smarter markets through improved tools, benchmarks, and technology to address significant societal challenges, including the energy transition [5]. - The company is the majority shareholder of Abaxx Singapore, which owns Abaxx Exchange and Abaxx Clearing, and operates Abaxx Spot, a platform for modernizing physical gold trading [6].

oils12,92212,59112,01211,927Solvents7,0787,3977,6757,494Waxes1,4961,4521,4051,415Fuels, asphalt and other by- products45,93739,81239,53736,390Total Specialty Products and indebtedness;- the financial performance of our assets without regard to financing methods, capital structure or historical cost basis;We believe that these non-GAAP measures are useful to analysts and investors, as they exclude transactions not related to our core cash operating activities and provide metrics to analyze our ability to fun ...

Core Insights - Telix Pharmaceuticals Limited has announced a research collaboration with University Hospital Essen to explore the prognostic value of PSMA-PET imaging through artificial intelligence [1][4]. Group 1: Research Collaboration - The PROMISE-PET registry is a multi-center, prospective, observational study aimed at assessing the prognostic value of PSMA-PET imaging and comparing it with established clinical risk scores [2]. - The registry has been collecting data since 2018, standardizing PET readings from over 15,000 patients across more than 50 institutions globally [2]. Group 2: AI and Imaging Technology - The collaboration aims to develop AI-based prediction models for survival using gallium-68 (Ga)-PSMA-11-PET imaging data, leveraging Telix's automated machine learning platform [3]. - PSMA-PET imaging is now considered a standard of care in prostate cancer management, offering greater accuracy than conventional imaging methods [3]. Group 3: Expert Commentary - Wolfgang Fendler, MD, emphasized the importance of Telix's involvement in enhancing risk stratification and informing future clinical guidelines [4]. - Simon Wail from Telix highlighted the significance of accessing a large, standardized PSMA-PET dataset for developing clinically relevant prognostic models [4]. Group 4: Company Overview - Telix Pharmaceuticals is focused on developing therapeutic and diagnostic radiopharmaceuticals, with operations in multiple countries including the U.S., U.K., and Japan [5]. - The company has received approvals for its first-generation PSMA-PET imaging agent, Illuccix®, in various global markets [6].

Group 1 - The article discusses the return of trade policy to the forefront of the investment landscape, highlighting the opportunities for stock pickers to look beyond headlines [1] - The Supreme Court's recent decision has reshaped tariff authority, impacting investment strategies and stock selection [1] - Steven Cress, as the Head of Quantitative Strategies at Seeking Alpha, emphasizes a data-driven approach to investment decisions, aiming to remove emotional biases [1] Group 2 - Seeking Alpha's platform includes a quantitative stock rating system and analytical tools designed to interpret data for investors, providing insights on investment directions [1] - The Alpha Picks initiative selects two attractive stocks to buy each month and determines optimal selling times, aiding long-term investors in portfolio management [1] - Steven Cress has over 30 years of experience in equity research, quantitative strategies, and portfolio management, positioning him as a knowledgeable figure in investment topics [1]

AES Reschedules Fourth Quarter & Full Year 2025 Financial Review Conference Call to March 3, 2026 [Accessibility Statement] Skip NavigationARLINGTON, Va., Feb. 27, 2026 /PRNewswire/ -- The AES Corporation (NYSE: AES) rescheduled its fourth quarter and full year 2025 financial review conference call, which was previously scheduled for Friday, February 27, 2026. The Company will now hold this call on Tuesday, March 3, 2026 at 10:00 a.m. Eastern Time (ET), following the filing of its Annual Report on Form 10-K ...